BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 12, 2004
 |  BioCentury  |  Strategy

Two ends against the middle

Although Chiron Corp.'s acquisition of Sagres Discovery Inc. doesn't remedy its thin clinical pipeline in cancer, CHIR thinks the deal lays the foundation for a renewable internal source of oncology compounds. In addition, Sagres' approach to target discovery is opposite that of CHIR and other companies that use expression data to infer whether a gene may be a good target.

Sagres' high throughput Oncogenome technology uses a retrovirus that integrates randomly into a genome and up-regulates genes in mice. The genes that cause cancer are then cloned and Sagres uses the Celera...

Read the full 450 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >